Is Jagsonpal Pharmaceuticals a good stock to invest in?

Jagsonpal Pharmaceuticals can be analyzed on the following key metrics - TTM P/E: 46.06 Sector P/E: 31.15 Dividend Yield: 0.87% D/E ratio: -

Jagsonpal Pharmaceuticals Share Price

Sector: Major Drugs

Powered by

591.65 +13.55 (2.34%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 565

Today’s High 603.5

52 Week Low 270.05

52 Week High 634.95

Key Metrics

Market Cap (In Cr) 1528.85
Beta 1.56
Div. Yield (%) 0.87
P/B 8.13
TTM P/E 46.06
Peg Ratio 7.01
Sector P/E 31.15
D/E 0.05
Open Price 575.1
Prev Close 578.1

View All Metrics

Jagsonpal Pharmaceuticals Analysis

Price Analysis

1 Week

1.17%
3 Months

54.56%
6 Month

64.2%
YTD

48.26%
1 Year

50.45%

Risk Meter

55% Low risk
55% Moderate risk
55% Balanced Risk
55% High risk
55% Extreme risk

Jagsonpal Pharmaceuticals News

Companies reporting their results on 26 July include IndusInd Bank, Power Grid Corporation, Shriram Finance, Cipla, InterGlobe Aviation, Bandhan Bank, Aarti Drugs, Amber Enterprises India, Cholamandalam Investment and Finance, KEC International, KFin Technologies, Latent View Analytics, Nuvama Wealth Management, Piramal Pharma, SBI Cards and Payment Services, and TTK Prestige, among others. (Photo: Reuters)

Premium

Stocks to watch: Mankind, TechM, IndiGo, Adani Green, DLF, Ashok Leyland

9 min read . 26 Jul 2024

View More News

Jagsonpal Pharmaceuticals Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2024

Total Revenue
208.7

Selling/ General/ Admin Expenses Total
48.49

Depreciation/ Amortization
1.66

Other Operating Expenses Total
43.86

Total Operating Expense
187.3

Operating Income
21.4

Net Income Before Taxes
29.87

Net Income
22.46

Diluted Normalized EPS
8.46

Period
2023

Total Revenue
236.71

Selling/ General/ Admin Expenses Total
99.29

Depreciation/ Amortization
1.18

Total Operating Expense
206.54

Operating Income
30.17

Net Income Before Taxes
34.81

Net Income
26.72

Diluted Normalized EPS
11.19

Period
2022

Total Revenue
217.58

Selling/ General/ Admin Expenses Total
101.76

Depreciation/ Amortization
1.53

Total Operating Expense
193.08

Operating Income
24.5

Net Income Before Taxes
26.64

Net Income
18.86

Diluted Normalized EPS
7.19

Period
2021

Total Revenue
187.95

Selling/ General/ Admin Expenses Total
53.98

Depreciation/ Amortization
1.09

Other Operating Expenses Total
34.11

Total Operating Expense
169.95

Operating Income
17.99

Net Income Before Taxes
21.87

Net Income
17.06

Diluted Normalized EPS
6.51

Period
2020

Total Revenue
158.57

Selling/ General/ Admin Expenses Total
50.37

Depreciation/ Amortization
1.13

Other Operating Expenses Total
43.47

Total Operating Expense
151.17

Operating Income
7.4

Net Income Before Taxes
9.41

Net Income
7.87

Diluted Normalized EPS
3

Period
2019

Total Revenue
166.83

Selling/ General/ Admin Expenses Total
46.61

Depreciation/ Amortization
1.02

Other Operating Expenses Total
38.03

Total Operating Expense
158.51

Operating Income
8.32

Net Income Before Taxes
9

Net Income
7.22

Diluted Normalized EPS
2.75

Period
2018

Total Revenue
126.6

Selling/ General/ Admin Expenses Total
41.88

Depreciation/ Amortization
0.32

Other Operating Expenses Total
34.65

Total Operating Expense
138.03

Operating Income
-11.43

Net Income Before Taxes
-11.63

Net Income
-11.55

Diluted Normalized EPS
-4.41

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Jagsonpal Pharmaceuticals Technical

Moving Average SMA

5 Day559.23
10 Day576.48
20 Day535.64

50 Day472.1
100 Day420.84
300 Day370.83

Jagsonpal Pharmaceuticals Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Unichem Laboratories
860.7
-20.9
-2.37
949.85
401.1
6059.82

Themis Medicare
287.6
1.2
0.42
313.65
152.65
2647.07

Jagsonpal Pharmaceuticals
591.65
13.55
2.34
634.95
270.05
1564.19

Ind-Swift Laboratories
106
1.95
1.87
186
89.5
626.32

Ambalal Sarabhai Enterprises
55.48
-0.37
-0.66
77.7
37.54
425.16

Jagsonpal Pharmaceuticals Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

23-Oct-24
Quarterly Results & Stock Split

07-Aug-24
Quarterly Results

20-May-24
Audited Results & Final Dividend

02-Feb-24
Quarterly Results

03-Nov-23
Quarterly Results

02-Aug-23
Quarterly Results

23-May-23
Audited Results & Dividend

08-Feb-23
Quarterly Results

09-Nov-22
Quarterly Results

09-Aug-22
Quarterly Results

Meeting Date
Announced on
Purpose

31-Aug-23
02-Aug-23
AGM

14-Sept-22
09-Aug-22
AGM

17-Jun-22
20-May-22
EGM

Announced on
Record Date
Ex-Dividend
Dividend Value

21-May-24
06-Sept-24
06-Sept-24
5

23-May-23
21-Aug-23
21-Aug-23
5

19-Oct-21
01-Nov-21
29-Oct-21
4

30-Jun-21
-
22-Sept-21
1

View All

Company Profile

ABOUT Jagsonpal Pharmaceuticals

Industry Major Drugs
ISIN INE048B01027
BSE Code 507789
NSE Code JAGSNPHARM

Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yuliprist, Deereg, and Lycored Softgel. Its Orthopaedics products include JP Tone Up, Metadec 50 Injection, Metadec 25 Injection, Indocap SR, and Indocap, Colla-2. Its other products include Equirex, Doxypal DR-L, JP Tone Syrup, and Lycored Syrup.

MANAGEMENT

Rajpal Kochhar Chairman of the Board, Managing Director
Ashish Lakhotia Chief Financial Officer
Abhishek Joshi Compliance Officer, Company Secretary
Manish Gupta Managing Director, Additional Director

JAGSONPAL PHARMACEUTICALS SUMMARY

Jagsonpal Pharmaceuticals is trading 2.34% upper at Rs 591.65 as compared to its last closing price. Jagsonpal Pharmaceuticals has been trading in the price range of 603.5 & 565. Jagsonpal Pharmaceuticals has given 48.26% in this year & 1.17% in the last 5 days.

Jagsonpal Pharmaceuticals has TTM P/E ratio 46.06 as compared to the sector P/E of 31.15.

The company posted a net profit of 11.46 Crores in its last quarter.

Listed peers of Jagsonpal Pharmaceuticals include Unichem Laboratories (-2.37%), Themis Medicare (0.42%), Jagsonpal Pharmaceuticals (2.34%) etc.

Jagsonpal Pharmaceuticals has a 67.97% promoter holding & 32.03% public holding.

FAQs about Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals is trading at 591.65 as on 21 Nov, 2024 3:53:26 PM. This is 2.34% upper as compared to its previous closing price of 578.1

The market capitalization of Jagsonpal Pharmaceuticals is 1528.85 Cr as on 21 Nov, 2024 3:53:26 PM.

The 52 wk high for Jagsonpal Pharmaceuticals is 634.95 whereas the 52 wk low is 270.05

Jagsonpal Pharmaceuticals can be analyzed on the following key metrics -

TTM P/E: 46.06
Sector P/E: 31.15
Dividend Yield: 0.87%
D/E ratio: -

Jagsonpal Pharmaceuticals reported a net profit of 22.46 Cr in 2024.

Jagsonpal Pharmaceuticals Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Jagsonpal Pharmaceuticals Share Price

Price Range

Price Range

Key Metrics

Jagsonpal Pharmaceuticals Analysis

Jagsonpal Pharmaceuticals News

Stocks to watch: Mankind, TechM, IndiGo, Adani Green, DLF, Ashok Leyland

Jagsonpal Pharmaceuticals Financials

Forecast

Forecast

Forecast

Jagsonpal Pharmaceuticals Technical

Jagsonpal Pharmaceuticals Peers

Jagsonpal Pharmaceuticals Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Jagsonpal Pharmaceuticals

MANAGEMENT

JAGSONPAL PHARMACEUTICALS SUMMARY

FAQs about Jagsonpal Pharmaceuticals

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue